BR112018000468A2 - 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b - Google Patents

4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b

Info

Publication number
BR112018000468A2
BR112018000468A2 BR112018000468-5A BR112018000468A BR112018000468A2 BR 112018000468 A2 BR112018000468 A2 BR 112018000468A2 BR 112018000468 A BR112018000468 A BR 112018000468A BR 112018000468 A2 BR112018000468 A2 BR 112018000468A2
Authority
BR
Brazil
Prior art keywords
azaindoles
substituted
receptor modulators
glun2b receptor
nr2b receptor
Prior art date
Application number
BR112018000468-5A
Other languages
English (en)
Inventor
C. Chrovian Christa
A. Letavic Michael
C. Rech Jason
Soyode-Johnson Akinola
L. Wall Jessica
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112018000468A2 publication Critical patent/BR112018000468A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

4-azaindóis substituídos como ligantes do receptor de nr2b. estes compostos podem ser usados na modulação do receptor de nr2b e em composições farmacêuticas e métodos para o tratamento de estados doentios, distúrbios e condições mediadas pela atividade do receptor de nr2b.
BR112018000468-5A 2015-07-09 2016-07-07 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b BR112018000468A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
US62/190,416 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (1)

Publication Number Publication Date
BR112018000468A2 true BR112018000468A2 (pt) 2018-09-18

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000468-5A BR112018000468A2 (pt) 2015-07-09 2016-07-07 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b

Country Status (25)

Country Link
US (2) US9963447B2 (pt)
EP (1) EP3319963B1 (pt)
JP (2) JP6964576B2 (pt)
KR (1) KR20180026760A (pt)
CN (1) CN108026094B (pt)
AU (1) AU2016291158B2 (pt)
BR (1) BR112018000468A2 (pt)
CA (1) CA2991765C (pt)
CY (1) CY1123007T1 (pt)
DK (1) DK3319963T3 (pt)
EA (1) EA033197B1 (pt)
ES (1) ES2781867T3 (pt)
HK (1) HK1255160A1 (pt)
HR (1) HRP20200410T1 (pt)
HU (1) HUE047460T2 (pt)
IL (1) IL256758A (pt)
LT (1) LT3319963T (pt)
MA (1) MA42397B1 (pt)
MD (1) MD3319963T2 (pt)
MX (1) MX2018000352A (pt)
PL (1) PL3319963T3 (pt)
PT (1) PT3319963T (pt)
SI (1) SI3319963T1 (pt)
WO (1) WO2017007938A1 (pt)
ZA (1) ZA201800827B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
HUE047460T2 (hu) 2015-07-09 2020-04-28 Janssen Pharmaceutica Nv Szubsztituált 4-azaindolok és ezek alkalmazása mint GLUN2B receptor modulátorok
AU2017217542B2 (en) 2016-02-10 2021-06-03 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピリジン及びピリミジン並びにｇｌｕｎ２ｂ受容体調節物質としてのそれらの使用
CR20210580A (es) * 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
WO2020249785A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
US20220324860A1 (en) 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CA3143105A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
CN114621125A (zh) * 2020-12-14 2022-06-14 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
BRPI0507501A (pt) 2004-02-18 2007-06-26 Astrazeneca Ab composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
US7807704B2 (en) * 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2167464B1 (en) 2007-05-25 2014-12-03 AbbVie Deutschland GmbH & Co KG Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US20100325949A1 (en) 2007-07-03 2010-12-30 Edward Scott Carlson Support apparatus for climbing plants
EA201070323A1 (ru) 2007-08-30 2010-10-29 Такеда Фармасьютикал Компани Лимитед Замещенное производное пиразола
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
EP2254580A1 (en) 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
EP2308877B1 (en) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
ES2466341T3 (es) * 2008-10-16 2014-06-10 Janssen Pharmaceuticals, Inc. Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
BR112015021549A2 (pt) * 2013-03-13 2017-07-18 Abbvie Inc inibidores de piridina cinase cdk9
CA2903293C (en) * 2013-03-15 2020-10-13 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
HUE047460T2 (hu) 2015-07-09 2020-04-28 Janssen Pharmaceutica Nv Szubsztituált 4-azaindolok és ezek alkalmazása mint GLUN2B receptor modulátorok
AU2017217542B2 (en) 2016-02-10 2021-06-03 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Also Published As

Publication number Publication date
IL256758A (en) 2018-03-29
PT3319963T (pt) 2020-04-09
JP6964576B2 (ja) 2021-11-10
LT3319963T (lt) 2020-03-25
EP3319963A1 (en) 2018-05-16
MD3319963T2 (ro) 2020-05-31
AU2016291158A1 (en) 2018-02-01
CA2991765C (en) 2023-10-03
JP2021193099A (ja) 2021-12-23
US9963447B2 (en) 2018-05-08
CN108026094B (zh) 2021-02-09
US10377753B2 (en) 2019-08-13
JP2018520170A (ja) 2018-07-26
US20170008890A1 (en) 2017-01-12
EA201890245A1 (ru) 2018-06-29
CN108026094A (zh) 2018-05-11
EA033197B1 (ru) 2019-09-30
AU2016291158B2 (en) 2020-04-30
CA2991765A1 (en) 2017-01-12
DK3319963T3 (da) 2020-02-03
MA42397B1 (fr) 2020-02-28
KR20180026760A (ko) 2018-03-13
ES2781867T3 (es) 2020-09-08
EP3319963B1 (en) 2020-01-08
SI3319963T1 (sl) 2020-02-28
CY1123007T1 (el) 2021-10-29
HUE047460T2 (hu) 2020-04-28
HRP20200410T1 (hr) 2020-08-21
MX2018000352A (es) 2018-08-15
ZA201800827B (en) 2019-09-25
US20180208595A1 (en) 2018-07-26
PL3319963T3 (pl) 2020-06-01
HK1255160A1 (zh) 2019-08-09
JP7369743B2 (ja) 2023-10-26
WO2017007938A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
BR112018000468A2 (pt) 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
BR112019006691A2 (pt) 1h-imidazo[4,5-b]piridin-2(3h)-onas substituídas e seu uso como moduladores do receptor de glun2b
BR112018016329A2 (pt) 1,2,3-triazóis substituídos como moduladores de nmda seletivos para nr2b
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
CL2021003257A1 (es) Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
PH12016500374A1 (en) Biaryl acetamide compounds and methods of use thereof
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
BR112021024856A2 (pt) Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
EA201690713A1 (ru) Гетероциклические соединения и их применения
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
BR112016021962A2 (pt) Compostos, composição farmacêutica e seus usos como moduladores de ror gama
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
BR112021024117A2 (pt) Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements